Glucose-6-phosphatase (Glu-6-Pase) catalyzes the terminal step of gluconeogenesis, the conversion of glucose 6-phosphate (Glu-6-P) to free glucose. This enzyme activity is thought to be conferred by a complex of proteins residing in the endoplasmic reticulum (ER), including a Glu-6-P translocase that transports Glu-6-P into the lumen of the ER, a phosphohydrolase catalytic subunit residing in the lumen, and putative glucose and inorganic phosphate transporters that allow exit of the products of the reaction. In this study, we have investigated the effect of adenovirus-mediated overexpression of the Glu-6-Pase catalytic subunit on glucose metabolism and insulin secretion, using a well differentiated insulinoma cell line, INS-1. We found that the overexpressed Glu-6-Pase catalytic subunit was normally glycosylated, correctly sorted to the ER, and caused a 10-fold increase in Glu-6-Pase enzymatic activity in in vitro assays. Consistent with these findings, a 4.2-fold increase in 3 H 2 O incorporation into glucose was observed in INS-1 cells treated with the recombinant adenovirus containing the Glu-6-Pase catalytic subunit cDNA (Ad-CMV-Glu-6-Pase). 3-[ 3 H]Glucose usage was decreased by 32% in AdCMV-Glu-6-Pase-treated cells relative to controls, resulting in a proportional 30% decrease in glucose-stimulated insulin secretion. Our findings indicate that overexpression of the Glu-6-Pase catalytic subunit significantly impacts glucose metabolism and insulin secretion in islet ␤-cells. However, INS-1 cells treated with AdCMV-Glu-6-Pase do not exhibit the severe alterations of ␤-cell function and metabolism associated with islets from rodent models of obesity and non-insulin-dependent diabetes mellitus, suggesting the involvement of genes in addition to the catalytic subunit of Glu-6-Pase in the etiology of such ␤-cell dysfunction.
1 catalyzes the terminal step in gluconeogenesis, the hydrolysis of glucose 6-phosphate (Glu-6-P) to free glucose. In liver, Glu-6-Pase plays an important role in regulating glucose disposal and storage in concert with the opposing actions of the glucose-phosphorylating enzyme glucokinase. Glucokinase is also an important regulator of glucose metabolism and glucose-stimulated insulin secretion in ␤-cells of the islets of Langerhans (1, 2) . The stimulation of insulin secretion by glucose is thought to be mediated by increases in the ATP:ADP ratio and closure of ATP-sensitive K ϩ channels (1, 3) . Glu-6-Pase has also been reported to be expressed in the islets of Langerhans (4), but measurements of enzyme activity have yielded conflicting results (4, 5) , and the extent to which the enzyme participates in regulation of glucose flux in normal islets remains unresolved.
Measurement of glucose formation and utilization in islets from an obese and insulin-resistant strain of rodents (the ob/ob mouse) has revealed a dramatically increased rate of incorporation of 3 H 2 O into glucose in such islets relative to those from normal lean animals (6, 7) . Glucose-stimulated insulin secretion is disturbed in these and other genetic models of obesity and non-insulin-dependent diabetes mellitus, and it has been suggested that active glucose recycling could contribute to the defect by causing increased consumption of ATP (7) . These metabolic studies have logically implied that the molecular basis for increased cycling in islets from ob/ob mice is enhanced expression of Glu-6-Pase (6, 7), but older studies in which the activity of the enzyme was compared in ob/ob versus normal mice revealed less than a 2-fold increase (8) , leaving unresolved the issue of the role of Glu-6-Pase expression in the activation of glucose recycling in the islet.
Further uncertainty about the effect of Glu-6-Pase overexpression in islets is introduced by the molecular complexity of this enzyme system. Glu-6-Pase activity is thought to be imparted in the cell by a set of proteins residing in the endoplasmic reticulum (9) . Included are a Glu-6-P translocase that transports Glu-6-P from the cytoplasm to the lumen of the endoplasmic reticulum, the Glu-6-Pase catalytic subunit or phosphohydrolase that resides in the lumen, and putative proteins that transport glucose and inorganic phosphate back to the cytoplasm. The cDNAs encoding the phosphohydrolase catalytic component of Glu-6-Pase from mouse, human, and rat have recently been cloned (10 -12) , and a glucose transporter isoform termed GLUT-7 has been reported to be localized in the endoplasmic reticulum (13) . To the extent that activities other than the phosphohydrolase component are rate-limiting for the system, overexpression of only the catalytic subunit may have limited metabolic impact.
More recently, a survey of expression of a large panel of genes by reverse transcriptase polymerase chain reaction in Zucker diabetic fatty (ZDF) rats revealed that the mRNA encoding the catalytic subunit of Glu-6-Pase is increased by approximately 43% in islets of prediabetic and by more than 5-fold in diabetic male ZDF animals relative to Zucker lean controls (14) . Impressively, Glu-6-Pase was one of only two genes among the 31 surveyed whose expression was increased in the obese and diabetic animals relative to controls. Like islets from ob/ob mice, those from ZDF rats have elevated rates of glucose usage and impaired regulation of insulin secretion (14 -16), but it is as yet uncertain whether increased expression of the Glu-6-Pase transcript results in increased enzymatic activity within islet cells or contributes to the dysfunctional phenotype in any way.
To address the issue of whether overexpression of the catalytic subunit of Glu-6-Pase is sufficient to activate glucose cycling and impair insulin secretion, we have used the recombinant adenovirus system to express this protein in the well differentiated INS-1 insulinoma cell line. We find that overexpression of the catalytic subunit of Glu-6-Pase in such cells has a clear metabolic impact and that impairment of glucose-stimulated insulin secretion is proportional to the resultant reduction in glycolytic flux.
MATERIALS AND METHODS
Cell Culture-INS-1 cells were grown in RPMI 1640 medium containing 11 mM glucose, 10% fetal calf serum, 10 mM Hepes, 2 mM glutamine, 1 mM sodium pyruvate, 50 mM ␤-mercaptoethanol, 100 milliunits of penicillin, and 100 mg of streptomycin/ml (17) . Primary hepatocytes were prepared from 200 -300-g male Wistar rats using the method of Massague and Guinovart (18) and cultured as described previously (19) .
Preparation and Use of Recombinant Adenovirus Containing the cDNA Encoding the Glu-6-Pase Catalytic Subunit-A recombinant adenovirus containing the cDNA encoding the rat Glu-6-Pase catalytic subunit (AdCMV-Glu-6-Pase) was prepared by methods described previously (20) . A 1.4-kilobase KpnI/EcoRI fragment encompassing the entire protein coding region but none of the 5Ј-untranslated region of the Glu-6-Pase cDNA was ligated to 320 base pairs of the 5Ј-untranslated region of the rat islet glucokinase cDNA (21) and inserted into the adenovirus cloning plasmid pACCMV-pLpA (22) . pACMV-pLpA containing the Glu-6-Pase cDNA was cotransfected with pJM17 plasmid (23) into 293 cells. The resultant recombinant virus was plaque purified, amplified, and isolated by CsCl gradient centrifugation to produce stocks with titers of approximately 10 10 virions/ml as described (20) . Titering of the virus was accomplished by measuring the optical density of the viral solution at 260 nm, using a conversion factor of 1 ϫ 10 12 virions/OD unit. INS-1 cells were left untreated or exposed to AdCMVGlu-6-Pase or a control virus containing the ␤-galactosidase gene (Ad-CMV-␤-gal; 24) for 1 h. In experiments with INS-1 cells, the viral incubation media was replaced with RPMI 1640 medium containing 10% fetal calf serum and 5 mM glucose for 40 -48 h before the biochemical analyses described below. Isolated hepatocytes were treated with recombinant viruses as described previously (19) .
Northern Blot-Total RNA was prepared by the Triazol method (Life Technologies, Inc.) from INS-1 cells or hepatocytes. RNA was electrophoresed on a 1.2% formaldehyde-agarose gel, transferred to nitrocellulose, and hybridized to 32 P-labeled Glu-6-Pase cDNA, prepared by the random primer method (25) .
Subcellular Fractionation and Immunoblot Analysis-INS-1 cells were sonicated for 3-5 s in ice-cold homogenization buffer containing 20 mM Tris, pH 7.0, 150 mM KF, 5 mM EDTA, 250 mM sucrose, 10 mg/ml leupeptin, 1 mM benzamidine, and 1 mM phenylmethylsulfonyl fluoride. Homogenization of fresh liver samples was carried out in the same homogenization buffer but using a 15-s burst with a Brinkmann homogenizer. Cell debris was removed by centrifugation at 12,000 ϫ g for 15 min, and the supernatant was recentrifuged at 105,000 ϫ g for 60 min. In some experiments, the low speed pellet was resuspended in 150 l of homogenization buffer and retained for analysis of Glu-6-Pase content. The 105,000 ϫ g microsomal pellet and supernatant fractions were recovered, the pellet resuspended in 150 l of homogenization buffer, and the supernatant fraction concentrated to approximately the same volume. The resuspended low speed pellet, high speed pellet, and supernatant fractions were prepared for SDS-polyacrylamide gel electrophoresis by mixing with an equal volume of 50 mM Tris, pH 7.0, 8 M urea, 1% SDS, and 5% ␤-mecaptoethanol and heating to 50°C. Electrophoretically resolved proteins were transferred to Immobilon P membrane (Millipore) and reacted with a 1:1,000 dilution of a polyclonal antiserum against the rat Glu-6-Pase catalytic subunit (a gift from Dr. R. Taub, University of Pennsylvania; 26), and the blot was developed with ECL reagents (Amersham).
Glycosylation of Recombinant Glu-6-Pase-Crude microsomes isolated from AdCMV-Glu-6-Pase-treated INS-1 cells or hepatocytes, or fresh liver harvested from a 24-h fasted rat, were pretreated with 1% Triton or 0.5% SDS on ice for 15 min and subsequently incubated for 10 min in 80 l of 50 mM Tris, pH 7.0, 1% Nonidet P-40, 0.2% SDS, 2 units/ml aprotinin, 2.5 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 1 mg/ml antipain, and 0.5-1 unit of recombinant N-glycosidase F (Boehringer Mannheim). Control samples were treated in the same fashion except in the absence of N-glycosidase F. In other experiments, 2.5 mg/ml tunicamycin was added to the culture medium of AdCMV-Glu-6-Pase-treated INS-1 cells or hepatocytes to inhibit glycosylation. The presence or absence of N-linked oligosaccharides was evaluated on the basis of electrophoretic mobility of Glu-6-Pase as determined by SDSpolyacrylamide electrophoresis and immunoblot analysis (see above).
Glu-6-Pase Enzyme Activity Assay-Glu-6-Pase enzymatic activity was measured in microsomal fractions of INS-1 cells or liver by the inorganic phosphate release assay of Nordlie and Arion (27) , using an assay kit from Sigma. Measurements were performed in the presence of either 200 mM Glu-6-P or 200 mM Man-6-P.
Glucose-stimulated Insulin Secretion-For insulin secretion experiments, untreated or AdCMV-Glu-6-Pase or AdCMV-␤-gal-treated INS-1 cells were washed twice with secretion buffer containing 20 mM Hepes, pH 7.4, 0.1 M NaCl, 4.5 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 2.5 mM CaCl 2 , 0.2% bovine serum albumin and preincubated with secretion buffer containing 2 mM glucose for 1 h at 37°C with 95% O 2 and 5% CO 2 . The preincubation medium was then replaced with secretion buffer containing varying glucose concentrations. After 3 h of incubation, the medium was collected and subjected to insulin radioimmunoassay, using the Coat-A-Count radioimmunoassay kit (Diagnostic Products Corporation, Los Angeles).
Metabolic Assays-Glucose usage in AdCMV-Glu-6-Pase or AdCMV-␤-gal-treated INS-1 cells was assayed by incubation with 3-or 5-[ 3 H] glucose and measurement of 3 H 2 O production as described previously (28) . In separate assays, 3 H 2 O incorporation into glucose was used to measure the rate of Glu-6-P dephosphorylation, using the method of Khan et al. (6, 7) , with some modifications. Briefly, approximately 1.5 ϫ 10 6 INS-1 cells were incubated in Krebs-bicarbonate buffer with 0.5% bovine serum albumin, 5 mM or 15 mM glucose, and 3 H 2 O (1.25 mCi/100 l medium; NEN Life Science Products). The reaction was terminated after 3 h of incubation at 37°C by adding an equal volume of 10% perchloric acid followed by neutralization of the supernatant with 1 M KOH. The insoluble proteins, cell debris, and potassium perchlorate were removed by centrifugation. An aliquot of the supernatant was freeze dried twice and dissolved in Krebs-bicarbonate buffer with 15 mM glucose. The 3 H-labeled glucose in the supernatant was then separated from other labeled media components by silica gel thin layer chromatography, using chloroform:acetic acid:H 2 O (30:35:5, v/v) as the mobile phase (29) . Glucose was visualized by staining with a 0.2% solution of naphthoresorcinol (in ethanol) and 20% H 2 SO 4 (1:1, v/v). The area of the thin layer chromatography plate staining positive for glucose was cut out, placed in scintillation fluid (Bio-Safe II, Research Products International), and counted. Lactate production in the medium was assayed as described (30) .
Statistical Analysis-Statistical significance was calculated by t test with two samples assuming unequal variances using the Microsoft Excel program. To evaluate further the expressed Glu-6-Pase gene products, crude microsomes isolated from AdCMV-Glu-6-Pase-treated INS-1 cells were subjected to immunoblot analysis with an antibody raised against the rat Glu-6-Pase catalytic subunit (24) . In the representative experiment shown in Fig. 2 , the antibody detected very low levels of a protein of approximately 36,000 daltons in untreated or AdCMV-␤-gal-treated INS-1 cells, although in other experiments, this band was not visible. Treatment of INS-1 cells with AdCMV-Glu-6-Pase caused a large increase in the expression of an immunodetectable protein of the same size as the native Glu-6-Pase gene product ( Fig. 2A) . Although the fold increase in Glu-6-Pase expression in AdCMV-Glu-6-Pase-treated INS-1 cells could not be monitored accurately because of the low levels of Glu-6-Pase protein in the control cells, densitometric analysis revealed that INS-1 cells treated with 4 ϫ 10 9 virions/1.5 ϫ 10 6 cells (the lowest viral dose tested) contained 2.6 times as much microsomal Glu-6-Pase protein as found in microsomes isolated from liver of an overnight fasted rat, whereas INS-1 cells treated with 1 ϫ 10 10 or 2 ϫ 10 10 virions/1.5 ϫ 10 6 cells expressed 6.1-and 8.3-fold more Glu-6-Pase protein, respectively. Importantly, the recombinant Glu-6-Pase expressed in INS-1 cells was detected at the same electrophoretic position as the endogenous Glu-6-Pase expressed in liver microsomes isolated from a 24-h fasted rat ( Fig. 2A) .
RESULTS

Expression of Glu-6-Pase via Recombinant Adenovirus-
Normal Post-translational Processing of the Recombinant Glu-6-Pase-To determine whether the overexpressed Glu-6-Pase protein was retained appropriately in the microsomal fraction as expression levels were increased by AdCMV-Glu-6-Pase treatment, we performed subcellular fractionation experiments at a low and a high viral titer. Three simple fractions were evaluated: the pellet of the initial 12,000 ϫ g spin, which should contain mitochondria and other cellular debris but relatively few microsomes; the microsomal pellet obtained by centrifugation at 105,000 ϫ g; and the supernatant fraction from this high speed spin. As can be seen in Fig. 2B , immunodetectable Glu-6-Pase was increased in proportion to viral dose in the microsomal pellet fraction and was the fraction with highest Glu-6-Pase expression at both the low (4 ϫ 10 9 virions/1.5 ϫ 10 6 cells) and high (2 ϫ 10 10 virions/1.5 ϫ 10 6 cells) titer. Very little Glu-6-Pase immunoreactivity was found in the high speed supernatant fraction at either viral titer, but a significant level was detected in the low speed pellet which increased with viral dose. It should be noted, however, that the percent of Glu-6-Pase found in the microsomal fraction was 63% at the low viral dose and 60% at the high dose, demonstrating that a similar proportion of the total Glu-6-Pase enzyme was found in microsomes for all conditions studied.
We also evaluated the glycosylation state of the expressed protein by incubation of AdCMV-Glu-6-Pase-treated cells with the glycosylation inhibitor tunicamycin or by incubation of microsomes from AdCMV-Glu-6-Pase-treated cells with N-glycosidase F. Consistent with a recent report showing that Glu-6-Pase is glycosylated via an N-linked site (31), the Glu-6-Pase protein produced in AdCMV-Glu-6-Pase-treated INS-1 cells migrated at a higher apparent molecular weight than the protein expressed in tunicamycin-treated cells or from N-glycosidase F-treated microsomes (Fig. 2C) . Immunodetectable, recombinant Glu-6-Pase from untreated and N-glycosidase F-treated INS-1 microsomes migrated identically with the endogenous Glu-6-Pase bands from untreated and N-glycosidase F-treated liver cells, respectively, indicating that the size of the oligosaccharide added to the recombinant protein in INS-1 cells is the same as that added to the native protein in normal liver (Fig.  2C) . The presence of appropriately glycosylated Glu-6-Pase in the microsomal fraction suggested that the recombinant enzyme was largely localized to the endoplasmic reticulum in AdCMV-Glu-6-Pase-treated INS-1 cells.
The Enzymatic Activity of Recombinant Glu-6-Pase-As shown in Table I 10 virions/1.5 ϫ 10 6 cells) resulted in Glu-6-P hydrolysis at a rate of 5.13 mol/min/mg of microsomal protein and a corresponding Man-6-P dephosphorylating activity of 2.41 mol/min/mg of microsomal protein. Thus, the ratio of Man-6-P to Glu-6-P dephosphorylation was approximately 47% for microsomes isolated either from fresh liver or AdCMV-Glu-6-Pase-treated INS-1 cells. Because Man-6-P is not dephosphorylated by Glu-6-Pase when it is contained in intact microsomes (9), our findings suggest a similar degree of "leakiness" or latency in the two preparations, allowing direct comparison of enzyme activities. Consistent with this, freezing and thawing of the two microsomal preparations, a manipulation that would be expected to cause rupturing of intact microsomes, resulted in an increase in the dephosphorylation rate for Man-6-P to a level approximately 80% the rate measured with Glu-6-P (data not shown). We conclude that treatment of INS-1 cells with the intermediate titer of AdCMV-Glu-6-Pase virus resulted in a Glu-6-Pase enzyme activity approximately 10 times that found in fasted rat liver. We also measured total glucose phosphorylating activity in extracts from untreated and AdCMV-Glu-6-Pase-treated INS-1 cells with a previously described radioisotopic assay (19) . We found that treatment with the AdCMV-Glu-6-Pase virus had no effect on glucosephosphorylating capacity (105.6 Ϯ 5.5 mol/g of protein/h in untreated cells versus 121.5 Ϯ 10.0 mol/g of protein/h in AdCMV-Glu-6-Pase-treated cells), indicating that the AdCMVGlu-6-Pase virus allows us to manipulate specifically Glu-6-Pase activity in INS-1 cells without affecting glucose phosphorylation.
Metabolic Impact of Glu-6-Pase Overexpression-The increase in enzyme activity measured in microsomes from Ad-CMV-Glu-6-Pase-treated INS-1 cells may not reflect changes in Glu-6-Pase activity in the intact cell. Therefore, we obtained a direct measure of the metabolic impact of overexpression of the catalytic subunit of Glu-6-Pase in INS-1 cells by assaying the incorporation of 3 H 2 O into glucose. 3 H 2 O labels newly formed glucose primarily at the hexose phosphate isomerase reaction (6, 7) . INS-1 cells treated with 1 ϫ 10 10 virions/1.5 ϫ 10 6 cells AdCMV-Glu-6-Pase (intermediate viral dose) produced 2.5-fold more labeled glucose than AdCMV-␤-gal-treated or untreated INS-1 cells when the medium contained 5 mM glucose (data not shown) and 4.2 times more when the medium glucose was set at 15 mM (Fig. 3) . These results indicate that the overexpressed Glu-6-Pase was metabolically active within intact INS-1 cells. Furthermore, the increase in labeled glucose production in AdCMV-Glu-6-Pase-treated cells as a function of medium glucose concentration indicates that increased glucose entry and phosphorylation are at least partially counterbalanced in these cells by enhanced "futile cycling" of glucose (glucose 7 Glu-6-P 7 Fru-6-P).
Although 3 H 2 O incorporation into glucose provides a direct measure of in vivo Glu-6-Pase activity that includes the recycling component, it does not provide a measure of the extent to which Glu-6-Pase overexpression may curtail glucose entry into the glycolytic pathway. To evaluate the latter we measured glucose usage and lactate production in AdCMV-Glu-6-Pasetreated and control INS-1 cells. In contrast to the large enhancement in 3 H 2 O incorporation into glucose, overexpression of Glu-6-Pase decreased 3-[ 3 H]glucose usage by only 32% compared with untreated cells and 23% compared with AdCMV-␤-gal-treated cells, although in both cases the changes were statistically significant (Fig. 4) . Similar findings were obtained if 5-[ 3 H]glucose was used, and lactate production, an independent measure of glycolytic flux, was decreased to an extent similar to that of glucose usage in AdCMV-Glu-6-Pase-treated cells (data not shown). Table II provides a summary of the metabolic data obtained at 15 mM glucose. Treatment of INS-1 cells with AdCMV-Glu-6-Pase increases the rate of incorporation of 3 H 2 O into glucose by 4.2-fold. Meanwhile, the rate of glucose phosphorylation (glucose usage ϩ the rate of glucose formation) is decreased by 23%. Thus, in untreated INS-1 cells, a very small percentage of the glucose that becomes phosphorylated is dephosphorylated (2.7%), whereas the extent of futile cycling in AdCMV-Glu-6-Pase-expressing cells is increased to 14.6%. Note that in these studies, we did not measure the percentage of 3 H incorporated into glucose which is found at carbon 2, as was done in the studies of Khan et al. (6, 7) . These authors found that approximately 45% of label was associated with carbon 2 of glucose in experiments with islets from either lean or ob/ob mice (7) . If one uses this number to correct our data to obtain an estimate of 3 H bound to carbon 2 of glucose (the most direct measure of glucose dephosphorylation), the extent of recycling is reduced to 1.2% in control INS-1 cells and 7.1% in AdCMV-Glu-6-Pase-treated cells.
Insulin Secretion in the AdCMV-Glu-6-Pase-treated Cells-To determine whether overexpression of the phosphohydrolase component of Glu-6-Pase in INS-1 cells impairs fuelmediated insulin secretion, we measured insulin secretion in response to glucose in control and AdCMV-Glu-6-Pase-treated INS-1 cells (the same intermediate viral titer as used for the metabolic studies was used for the insulin secretion experi- fresh liver Microsomes were prepared from untreated INS-1 cells, AdCMV-Glu-6-Pase-treated INS-1 cells, and freshly isolated liver from fasted rats and used for measurement of Glu-6-Pase activity with either 200 mM Glu-6-P or 200 mM Man-6-P as substrate. Values are expressed as mol of phosphate produced/min/mg of microsomal protein and represent the mean Ϯ S.E. for three independent determinations for the AdCMV-Glu-6-Pase-treated INS-1 cells and the mean of two independent determinations for the liver experiments. The ratio of activity measured in the presence of Man-6-P to that in the presence of Glu-6-P is also shown. Hydrolysis of Glu-6-P or Man-6-P was not detectable in untreated INS-1 cells (ND). AdCMV-Glu-6-Pase in INS-1 Cellsments). As shown in Fig. 5 , overexpression of Glu-6-Pase caused a small but significant reduction in insulin secretion in response to stimulatory glucose (15 mM) which was similar in magnitude to the reduction in glycolytic flux (30% reduction in insulin secretion, 32% reduction in glucose usage).
DISCUSSION
In this study, we have investigated the impact of overexpression of the Glu-6-Pase catalytic subunit in islet ␤-cells on glucose metabolism and glucose-stimulated insulin secretion. Whereas studies in other laboratories have implied that upregulation of this gene product could contribute to islet dysfunction in animals with obesity and non-insulin-dependent diabetes mellitus (6, 7, 8, 15) , no direct link between the phosphohydrolase component of the Glu-6-Pase system and glucose cycling and ␤-cell dysfunction had been established before our study.
Treatment of INS-1 cells with increasing titers of AdCMVGlu-6-Pase resulted in roughly proportional increases in Glu-6-Pase mRNA, protein, and enzyme activity. Importantly, posttranslational processing of the enzyme appeared normal by several criteria. First, like the native enzyme, the recombinant Glu-6-Pase was glycosylated with an N-linked oligosaccharide, as demonstrated by the complete conversion of a large form of the protein to a smaller form by either N-glycosidase F or tunicamycin treatment of AdCMV-Glu-6-Pase-treated cells. Second, subcellular fractionation experiments demonstrated that most of the Glu-6-Pase immunoreactivity was localized in the microsomal pellet and that the proportion found in the microsomes relative to other subcellular fractions remained the same for all levels of enzyme overexpression. Consistent with these data, treatment of INS-1 cells with an intermediate titer of AdCMV-Glu-6-Pase caused a 10-fold increase in microsomal Glu-6-Pase enzymatic activity. We conclude that the recombinant, overexpressed Glu-6-Pase is retained in the endoplasmic reticulum in a manner similar to that described for the native enzyme. The localization of the recombinant enzyme in the endoplasmic reticulum (microsomal fraction) is consistent with a functional endoplasmic reticulum retention motif in the primary sequence of the enzyme (31) .
The foregoing results, although demonstrating adenovirusmediated overexpression of the Glu-6-Pase catalytic subunit, did not establish that the overexpressed enzyme was catalytically active in vivo because in cells with fully intact endoplasmic reticulum, components of the Glu-6-Pase system other than the phosphohydrolase may be rate-limiting. Indeed, it has been suggested that the "latency" of intact microsomal preparations for Glu-6-P (i.e. the higher rate of dephosphorylation of Glu-6-P in detergent-permeabilized microsomes compared with intact microsomes) is reflective of a rate-limiting function of the translocase (9) . This is one reason that the increase in Glu-6-Pase phosphohydrolase mRNA documented in islets of ZDF rats (14) cannot automatically be expected to increase glucose cycling or otherwise impact glucose metabolism. We found that treatment of INS-1 cells with AdCMV-Glu-6-Pase caused a substantial (4.2-fold) increase in the incorporation of 3 H 2 O into medium glucose. This provides the first direct evidence that overexpression of the phosphohydrolase component alone causes increased flux through the Glu-6-Pase system. There is some evidence that other components of the system do provide some restraint on metabolic impact. At the intermediate titer of AdCMV-Glu-6-Pase virus used to cause the 4.2-fold increase in glucose production, INS-1 microsomes had 10 times the Glu-6-Pase enzymatic activity as liver microsomes from a fasted rat. The enhancement in enzyme activity in microsomes from Ad-CMV-Glu-6-Pase-treated INS-1 cells versus control INS-1 was obviously much larger than 10-fold, given that Glu-6-Pase activity was undetectable in control INS-1 cells with the assay employed. Thus, the difference between the change in total enzyme activity and the change in glucose production is substantial and may indicate that the metabolic impact of the overexpressed Glu-6-Pase catalytic subunit is ultimately limited by other components of the system.
Mechanisms other than the complexity of the Glu-6-Pase system itself also seem to limit the metabolic impact of Ad-CMV-Glu-6-Pase treatment. Thus, we found that overexpression of Glu-6-Pase caused only a 30% reduction in the rate of 3-or 5-[ relative to controls. These changes in metabolic flux were proportional to changes in glucose-stimulated insulin secretion. Thus, insulin secretion from AdCMV-Glu-6-Pase-treated INS-1 cells was reduced by 30% relative to either population of control cells in response to a maximally stimulatory concentration of glucose (15 mM). Insight into the limited impact of a large increase in Glu-6-P hydrolysis (as measured by 3 H 2 O incorporation into glucose) on overall glycolytic flux and glucose-stimulated insulin secretion is provided in part by inspection of the data in Table II . Here we see that if one considers the rate of Glu-6-P hydrolysis relative to the rate of glucose utilization as a measure of "glucose cycling," control INS-1 cells dephosphorylate or recycle only 2.7% (1.2% when corrected for labeling of carbon 2 of glucose) of the glucose that they utilize. In contrast, INS-1 cells overexpressing Glu-6-Pase increase the percentage of glucose that is recycled to 14.6% (7.1% corrected), but this still represents a relatively small fraction of the total glucose utilization. We interpret these findings to mean that INS-1 cells, which have levels of GLUT-2 and glucokinase similar to those of normal ␤-cells (32) , are able to maintain effective input of glucose into glycolytic flux even in the presence of a high level of expression of Glu-6-Pase. These findings may indicate that not all glucose that is phosphorylated by glucokinase is readily accessible to Glu-6-Pase, i.e. some of the glucose may be "channeled" directly into glycolysis. Further work will be required to clarify this intriguing issue.
It is interesting to compare our findings with those of Efendic and co-workers (7), who performed similar metabolic measurements on islets from ob/ob and normal mice. These investigators found a 56-fold increase in 3 H 2 O incorporation into glucose from islets of ob/ob mice compared with lean controls, versus only a 4.2-fold increase in the same parameter measured in our own experiments in AdCMV-Glu-6-Pase-treated INS-1 cells. Further, ob/ob islets exhibit an approximately 4-fold increase in 5-[
3 H]glucose usage rather than a 30% decrease as noted in our studies, possibly because of increased expression of low K m hexokinases in the former group (16, 30) . Older studies suggest that ob/ob islets have only about two times as much Glu-6-Pase enzymatic activity as islets from lean control mice (8) . Similarly, increases in Glu-6-Pase mRNA of approximately 50% in obese, prediabetic ZDF rats and of about 5-fold in diabetic ZDF animals have been reported by Bell and co-workers (14) . Such small changes could not account for the huge increase in glucose cycling observed in the ob/ob animals. Further, our work suggests that overexpression of the Glu-6-Pase catalytic subunit alone will be limited in metabolic impact. Thus, it is likely that the profound changes in glucose production observed in islets from ob/ob mice can not be ascribed to changes in expression of the Glu-6-Pase catalytic subunit alone and that changes in expression of other proteins, possibly including elements of the Glu-6-Pase system such as the Glu-6-P translocase, are required for the fully dysfunctional islet phenotype.
